Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis

Atherosclerosis

Volumn 224, Issue 1, 2012, Pages 218-221

  Mehta, Nehal N ^a   Li, Ron ^a   Krishnamoorthy, Parasuram ^a   Yu, YiDing ^a   Farver, William ^a   Rodrigues, Amrith ^a   Raper, Anna ^a   Wilcox, Mackenzie ^a   Baer, Amanda ^a   DerOhannesian, Stephanie ^a   Wolfe, Megan ^a   Reilly, Muredach P ^a   Rader, Daniel J ^a   VanVoorhees, Abby ^a   Gelfand, Joel M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Atherosclerosis; Cholesterol; HDL efflux; Inflammation; Lipoprotein particles

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIABETES MELLITUS; EFFUSION; EX VIVO STUDY; FEMALE; HUMAN; IN VIVO STUDY; INCUBATION TIME; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RISK FACTORS;

EID: 84865395015     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.06.068     Document Type: Article

References (17)

1. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc 2006, 296:1735-1741.
2. Gelfand J.M., Dommasch E.D., Shin D.B., et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009, 129:2411-2418.
3. Mehta N.N., Azfar R.S., Shin D.B., Neimann A.L., Troxel A.B., Gelfand J.M. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 2010, 31:1000-1006.
4. Mehta N.N., Yu Y., Pinnelas R., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011, 124(775):e771-e776.
5. Ahlehoff O., Gislason G.H., Charlot M., et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011, 270:147-157.
6. Armstrong A.W., Harskamp C.T., Ledo L., Rogers J.H., Armstrong E.J. Coronary artery disease in patients with psoriasis referred for coronary angiography. Am J Cardiol 2012.
7. Li W.Q., Han J.L., Manson J.E., et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. Women: a cohort study. Br J Dermatol 2012, 166:811-818.
8. Otvos J.D., Mora S., Shalaurova I., Greenland P., Mackey R.H., Goff D.C. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 2011, 5:105-113.
9. Kathiresan S., Otvos J.D., Sullivan L.M., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham heart study. Circulation 2006, 113:20-29.
10. 18f]-fluorodeoxyglucose positron emission tomography-computed tomography (fdg-pet/ct): a pilot study. Arch Dermatol 2011, 147:1031-1039.
11. Langan S.M., Seminara N.M., Shin D.B., et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012, 132:556-562.
12. de la Llera Moya M., McGillicuddy F.C., Hinkle C.C., et al. Inflammation modulates human hdl composition and function in vivo. Atherosclerosis 2012.
13. McGillicuddy F.C., de la Llera Moya M., Hinkle C.C., et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009, 119:1135-1145.
14. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
15. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
16. Tsai J., Zhang R., Qiu W., Su Q., Naples M., Adeli K. Inflammatory nf-kappab activation promotes hepatic apolipoprotein b100 secretion: evidence for a link between hepatic inflammation and lipoprotein production. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1287-G1298.
17. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.